April 14, 2013

$PVCT: Post-AACR...

What now? AACR is finished. Two posters displayed: Moffitt and Provectus. Moffit's poster presentation displayed definitive data on PV-10's tumor-specific immunity (i.e., how PV-10 harnesses the immune system). Provectus' showed PV-10's orthogonality (i.e., how PV-10-based combination therapy can be efficacious for inaccessible tumor burden).

There are key questions to explore over the near-term. Among them:
  • The FDA. Was the FDA convinced this local regional treatment can provide a systemic benefit to cancer patients? As the first intralesionally-injected compound that leads to the induction of tumor-specific immunity, does the FDA now understand the systemic benefit component of PV-10?
  • Big Pharma. By providing not only anti-tumor immunity, but also inducing tumor-specific immunity, does Big Pharma now understand the systemic potential of PV-10?
My students competed well in London, but Wroclaw University of Economics are CFA Institute Research Challenge Global Final champions. "The CFA Institute Research Challenge is an annual global competition that provides university students with hands-on mentoring and intensive training in financial analysis and professional ethics. Students are tested on their analytic, valuation, report writing and presentation skills, and gain real-world experience as they assume the role of an equity research analyst. More than 3,500 students from over 755 universities in 55 countries participated in the 2012-2013 Research Challenge." To be that close will sting them (and me) for a while, but I think they'll harness this experience and success as they embark on their careers.

No comments:

Post a Comment